Amsterdam, the Netherlands— May 6, 2025 
Essange Reagents is pleased to announce the appointment of Klaus Gögelein as Chief Executive Officer, effective May 6, 2025. Klaus brings decades of leadership experience in the field of In Vitro Diagnostic and a strong track record of driving strategic innovation and sustainable growth in the diagnostics sector.

In his new role, Klaus will lead the company’s global operations and strategic direction, with a clear focus on accelerating growth, expanding innovation, and advancing the company’s mission to support healthcare professionals worldwide in delivering accurate, reliable diagnoses.

“I am honored and excited to join Essange Reagents as CEO,” said Klaus Gögelein. “This is a company with a powerful mission and a passionate team. I look forward to building on the strong foundation that has been laid, and to working with our teams across the globe to bring diagnostic excellence to customers and patients worldwide.”

Klaus succeeds Wim Schimmel, who has played a pivotal role in strengthening Essange Reagents’ market position over the past years. The company extends its deepest gratitude to Wim for his dedicated leadership and contributions to the organization.

“We are thrilled to welcome Klaus to Essange Reagents,” said Hugo de Bruin, partner at Gilde Healthcare. “His deep expertise in IVD, combined with his clear vision and collaborative leadership style, make him the ideal person to lead us into the next phase of growth and innovation.”

Essange Reagents remains committed to delivering high-quality, reliable reagents that enable precision diagnostics, advancing patient care around the world.

About Essange Reagents
Essange Reagents is a global leader in specialized diagnostic reagents, committed to supporting healthcare professionals with innovative and reliable tools for accurate diagnostics. With a focus on quality, compliance, and customer partnership, Essange helps laboratories around the world make meaningful clinical decisions every day.